vs

Side-by-side financial comparison of AVIENT CORP (AVNT) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

AVIENT CORP is the larger business by last-quarter revenue ($760.6M vs $487.7M, roughly 1.6× CLOVER HEALTH INVESTMENTS, CORP.). AVIENT CORP runs the higher net margin — 2.2% vs -10.1%, a 12.3% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 1.9%). AVIENT CORP produced more free cash flow last quarter ($125.4M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -4.2%).

Avient Corporation is a global materials solutions company headquartered in Avon Lake, Ohio, United States, employing approximately 9,000 people worldwide. Its products include colorants, advanced composites, functional additives and engineered materials.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

AVNT vs CLOV — Head-to-Head

Bigger by revenue
AVNT
AVNT
1.6× larger
AVNT
$760.6M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+42.8% gap
CLOV
44.7%
1.9%
AVNT
Higher net margin
AVNT
AVNT
12.3% more per $
AVNT
2.2%
-10.1%
CLOV
More free cash flow
AVNT
AVNT
$194.4M more FCF
AVNT
$125.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-4.2%
AVNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVNT
AVNT
CLOV
CLOV
Revenue
$760.6M
$487.7M
Net Profit
$16.9M
$-49.3M
Gross Margin
30.2%
Operating Margin
5.2%
-10.1%
Net Margin
2.2%
-10.1%
Revenue YoY
1.9%
44.7%
Net Profit YoY
-65.0%
-123.2%
EPS (diluted)
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVNT
AVNT
CLOV
CLOV
Q4 25
$760.6M
$487.7M
Q3 25
$806.5M
$496.6M
Q2 25
$866.5M
$477.6M
Q1 25
$826.6M
$462.3M
Q4 24
$746.5M
$337.0M
Q3 24
$815.2M
$331.0M
Q2 24
$849.7M
$356.3M
Q1 24
$829.0M
$346.9M
Net Profit
AVNT
AVNT
CLOV
CLOV
Q4 25
$16.9M
$-49.3M
Q3 25
$32.6M
$-24.4M
Q2 25
$52.6M
$-10.6M
Q1 25
$-20.2M
$-1.3M
Q4 24
$48.3M
$-22.1M
Q3 24
$38.2M
$-9.2M
Q2 24
$33.6M
$7.4M
Q1 24
$49.4M
$-19.2M
Gross Margin
AVNT
AVNT
CLOV
CLOV
Q4 25
30.2%
Q3 25
30.4%
Q2 25
32.1%
Q1 25
31.8%
Q4 24
34.8%
Q3 24
32.1%
24.5%
Q2 24
30.3%
30.3%
Q1 24
33.6%
23.6%
Operating Margin
AVNT
AVNT
CLOV
CLOV
Q4 25
5.2%
-10.1%
Q3 25
8.3%
-4.9%
Q2 25
11.1%
-2.2%
Q1 25
0.1%
-0.3%
Q4 24
11.5%
-6.4%
Q3 24
9.5%
-2.7%
Q2 24
8.5%
2.0%
Q1 24
11.3%
-6.5%
Net Margin
AVNT
AVNT
CLOV
CLOV
Q4 25
2.2%
-10.1%
Q3 25
4.0%
-4.9%
Q2 25
6.1%
-2.2%
Q1 25
-2.4%
-0.3%
Q4 24
6.5%
-6.6%
Q3 24
4.7%
-2.8%
Q2 24
4.0%
2.1%
Q1 24
6.0%
-5.5%
EPS (diluted)
AVNT
AVNT
CLOV
CLOV
Q4 25
$0.18
Q3 25
$0.36
Q2 25
$0.57
Q1 25
$-0.22
Q4 24
$0.53
Q3 24
$0.41
Q2 24
$0.36
Q1 24
$0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVNT
AVNT
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$78.3M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$2.4B
$308.7M
Total Assets
$6.0B
$541.0M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVNT
AVNT
CLOV
CLOV
Q4 25
$78.3M
Q3 25
Q2 25
Q1 25
Q4 24
$194.5M
Q3 24
$288.0M
Q2 24
$254.8M
Q1 24
$208.3M
Total Debt
AVNT
AVNT
CLOV
CLOV
Q4 25
$1.9B
Q3 25
$2.0B
Q2 25
$2.0B
Q1 25
$2.1B
Q4 24
$2.1B
Q3 24
$2.1B
Q2 24
$2.1B
Q1 24
$2.1B
Stockholders' Equity
AVNT
AVNT
CLOV
CLOV
Q4 25
$2.4B
$308.7M
Q3 25
$2.4B
$340.9M
Q2 25
$2.4B
$344.2M
Q1 25
$2.3B
$336.1M
Q4 24
$2.3B
$341.1M
Q3 24
$2.4B
$342.2M
Q2 24
$2.3B
$324.9M
Q1 24
$2.3B
$292.5M
Total Assets
AVNT
AVNT
CLOV
CLOV
Q4 25
$6.0B
$541.0M
Q3 25
$6.1B
$559.7M
Q2 25
$6.1B
$575.0M
Q1 25
$5.8B
$583.7M
Q4 24
$5.8B
$580.7M
Q3 24
$6.0B
$653.0M
Q2 24
$5.9B
$674.2M
Q1 24
$5.9B
$671.8M
Debt / Equity
AVNT
AVNT
CLOV
CLOV
Q4 25
0.81×
Q3 25
0.83×
Q2 25
0.86×
Q1 25
0.90×
Q4 24
0.89×
Q3 24
0.88×
Q2 24
0.90×
Q1 24
0.90×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVNT
AVNT
CLOV
CLOV
Operating Cash FlowLast quarter
$167.8M
$-66.9M
Free Cash FlowOCF − Capex
$125.4M
$-69.0M
FCF MarginFCF / Revenue
16.5%
-14.1%
Capex IntensityCapex / Revenue
5.6%
0.4%
Cash ConversionOCF / Net Profit
9.93×
TTM Free Cash FlowTrailing 4 quarters
$195.0M
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVNT
AVNT
CLOV
CLOV
Q4 25
$167.8M
$-66.9M
Q3 25
$72.1M
$12.1M
Q2 25
$112.8M
$5.4M
Q1 25
$-51.1M
$-16.3M
Q4 24
$122.6M
$34.8M
Q3 24
$71.1M
$50.0M
Q2 24
$105.9M
$44.8M
Q1 24
$-42.8M
$25.9M
Free Cash Flow
AVNT
AVNT
CLOV
CLOV
Q4 25
$125.4M
$-69.0M
Q3 25
$47.4M
$11.4M
Q2 25
$85.8M
$4.8M
Q1 25
$-63.6M
$-16.5M
Q4 24
$81.5M
$33.3M
Q3 24
$46.1M
$49.6M
Q2 24
$74.5M
$44.4M
Q1 24
$-67.2M
$25.5M
FCF Margin
AVNT
AVNT
CLOV
CLOV
Q4 25
16.5%
-14.1%
Q3 25
5.9%
2.3%
Q2 25
9.9%
1.0%
Q1 25
-7.7%
-3.6%
Q4 24
10.9%
9.9%
Q3 24
5.7%
15.0%
Q2 24
8.8%
12.5%
Q1 24
-8.1%
7.3%
Capex Intensity
AVNT
AVNT
CLOV
CLOV
Q4 25
5.6%
0.4%
Q3 25
3.1%
0.1%
Q2 25
3.1%
0.1%
Q1 25
1.5%
0.0%
Q4 24
5.5%
0.5%
Q3 24
3.1%
0.1%
Q2 24
3.7%
0.1%
Q1 24
2.9%
0.1%
Cash Conversion
AVNT
AVNT
CLOV
CLOV
Q4 25
9.93×
Q3 25
2.21×
Q2 25
2.14×
Q1 25
Q4 24
2.54×
Q3 24
1.86×
Q2 24
3.15×
6.04×
Q1 24
-0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVNT
AVNT

Color Additives And Inks$466.0M61%
Specialty Engineered Materials$295.5M39%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons